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Mesenchymal, but not hematopoietic, stem cells can be mo-
bilized and differentiate into cardiomyocytes after myocardial
infarction in mice. Bone marrow (BM) cells are reported to
contribute to the process of regeneration following myocardial
infarction. The present study examined two independent clonal
studies to determine the origin of bone marrow (BM)-derived
cardiomyocytes. First, we transplanted single CD34−c-kit+Sca-
1+lineage− side population cells (hematopoietic stem cells)
from enhanced green fluorescent protein (EGFP)-transgenic
mice into lethally irradiated mice, induced myocardial infarc-
tion, and treated them with G-CSF to mobilize stem cells. At
8 weeks, we could not find any EGFP+ cardiomyocytes. In con-
trast, more than 5000 EGFP+ cardiomyocytes were observed
in whole BM cell-transplanted mice, suggesting that they were
derived from non-hematopoietic cells. Next, clonally purified
mesenchymal stem cells (MSC) that expressed EGFP in the
cardiomyocyte-specific manner were transplanted directly into
BM of lethally irradiated mice, and similar experiment was per-
formed. EGFP+ actinin+ cells were observed in the ischemic
myocardium, indicating that MSC had been mobilized and dif-
ferentiated into cardiomyocytes. Together, these results suggest
that the origin of the BM-derived cardiomyocytes is MSC.
Bone marrow cells can contribute to regeneration pro-
cesses in various tissues [1]. Cardiomyocytes derived from
bone marrow cells have been observed after myocardial
infarction [2, 3], and bone marrow–derived cells mobi-
lized by cytokines were capable of regenerating the my-
ocardial tissue, leading to an improvement in survival
and cardiac function after myocardial infarction [4]. Bone
marrow contains both hematopoietic and nonhematopoi-
etic cells, and the origin of the bone marrow cells with the
ability to repair damaged myocardial tissue remains un-
known. The identification of specific cell types involved
in myocardial repair is a crucial step toward the develop-
ment of effective stem cell-based therapies for myocar-
dial infarction.
The most likely candidates for the bone marrow–
derived stem cells with the ability to regenerate myocar-
dial tissue are hematopoietic stem cells (HSCs) [2–4] and
nonhematopoietic mesenchymal stem cells (MSCs) [5–
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8]. It was reported that bone marrow–derived cardiomy-
ocytes sporadically detected in noninfarcted mice were
exclusively generated by fusion with donor CD45+ cells,
possibly hematopoietic cells [9], suggesting that the so-
called phenomenon of HSCs “plasticity” might result
from the fusion of HSCs with cells residing in the target
tissue. Two recent studies reported that HSCs are unable
to differentiate into cardiomyocytes in vivo even after
myocardial infarction [10, 11]. MSCs are also candidates
for the regeneration of cardiomyocytes in vivo; we pre-
viously reported that bone marrow–derived MSCs could
differentiate into spontaneously beating cardiomyocytes
in vitro [5, 6], and other groups have repaired the my-
ocardium using MSCs transplantation in vivo [7, 8].
Here we report the precise origin of the bone mar-
row cells mobilized by cytokines to repair infarcted my-
ocardium. We transplanted genetically marked single
HSCs or clonal MSCs into lethally irradiated recipient
mice, induced myocardial infarction, treated the mice
with granulocyte-colony-stimulating factor (G-CSF), and
analyzed the cardiac tissues. Our results suggest that
MSCs are the predominant source of regenerated car-
diomyocytes.
SINGLE HSC PROGENY IS NOT A MAJOR
SOURCE OF NEW CARDIOMYOCYTES AFTER
CYTOKINE-ENHANCED POSTMYOCARDIAL
INFARCTION REPAIR
Matsuzaki et al [12] demonstrated that a single-cell
transplantation analysis using cells that had the strongest
dye-efflux activity (“Tip”-SP cells) with a phenotype
of CD34− c-Kit+Sca-1+Lin− (CD34− KSL-SP) exhib-
ited nearly complete (∼96%) level of hematopoietic
engraftment activity. To examine the contribution of
bone marrow–derived HSCs to the regeneration of car-
diomyocytes after myocardial infarction, either whole
bone marrow cells or single CD34− KSL-SP cells from
transgenic enhanced green fluorescent protein (EGFP)
mice were transplanted into irradiated mice. Myocardial
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Fig. 1. Granuloctye-colony-stimulating fac-
tor (G-CSF)–induced mobilization of bone
marrow (BM) cells in mice transplanted
with single CD34− c-kit+Sca-1+lineage−
side population (CD34− KSL-SP) cells or
whole bone marrow cells following myco-
cardial infarction. (A) Experimental proto-
col. Single EGFP+ CD34− KSL-SP cells and
radioprotective. EGFP− bone marrow cells
were transplanted into the recipient mice.
(B) The nucleated cell counts (NCC) for pe-
ripheral blood samples obtained 24 hours af-
ter the last injection of G-CSF (N = 10) or
saline (N = 10) are shown. Black bars in-
dicate EGFP+ cells and striped bars indi-
cate EGFP− cells. NS, not significant. ∗P <
0.0001. (C to F) Representative results for
immunofluorescent analysis using anti-GFP
antibody and TOTO-3 dye in the hearts of
mice transplanted with whole bone marrow
(w-BM) cells or single CD34− KSL-SP cells
separated from the bone marrow of trans-
genic EGFP mice. The green and blue sig-
nals indicate EGFP and nuclei, respectively.
Saline-treated mice (G-CSF (−) mice) (C)
and G-CSF–treated mice (G-CSF (+) mice)
(D) in the whole bone marrow group. G-CSF
(−) mice (E) and G-CSF (+) mice (F) in the
CD34− KSL-SP group (bars indicate 200 lm.
(G) The control experiment using C57BL/6J
mice as donors revealed that no green fluo-
rescence was detected in the whole heart (bar
indicates 50 lm). (H to J) Coimmunostaining
with anti-GFP and antiactinin antibodies in
the infarcted myocardium of G-CSF (+) mice
transplanted with whole bone marrow (H and
I) or single CD34− KSL-SP cells (J). The
green, red, and blue signals indicate EGFP,
actinin, and nuclei, respectively. (H and I) In
the whole bone marrow group, some of the
EGFP+ cells in the infarcted area were also
positive for actinin and showed striation, in-
dicating that they had differentiated into car-
diomyocytes. j, In contrast, very few EGFP+
actinin+ cells were seen in the infarcted area
in the CD34− KSL-SP group [bars indicate
50 lm (H and I) and 20 lm (J)].
infarction was induced and the mice were treated with
G-CSF daily for 10 days to mobilize the bone mar-
row cells to the heart. Histologic analysis was ex-
amined at 8 weeks (Fig. 1). The peripheral blood
nucleated cell counts, measured 24 hours after the last
injection of G-CSF, were significantly higher in the
G-CSF–treated [G-CSF(+)] mice than in saline-injected
[G-CSF(−)] mice. No significant difference in the nucle-
ated cell counts of G-CSF(+) mice was observed between
the whole bone marrow group and the CD34− KSL-SP
group.
A histologic analysis showed a markedly higher de-
gree of EGFP+ cell infiltration into the infarcted area in
G-CSF(+) mice than in G-CSF(−) mice. Among the G-
CSF(+) mice, a greater degree of infiltration was seen in
the whole bone marrow group than in the CD34− KSL-
SP group. In the whole bone marrow group, some of the
EGFP+ cells in the ischemic area expressed actinin and
showed striations, suggesting that they were cardiomy-
ocytes. Very few EGFP+ actinin+ cells were seen in the
two CD34− KSL-SP groups, which was consistent with
previous reports [10, 11]. The marked increase in EGFP+
actinin+ cells in the whole bone marrow groups cannot
be explained simply by the superiority of hematopoietic
chimerism in the whole bone marrow group (87% vs.
63%) if regenerated cardiomyocytes were derived from
HSCs. Collectively, these results suggest that the major
population of cells mobilized from the bone marrow and
active in the regeneration of cardiomyocytes was non-
hematopoietic in origin.
CLONAL MSC PROGENY CONTRIBUTES TO
THE REGENERATION OF CARDIOMYOCYTES
AFTER CYTOKINE-ENHANCED
POSTMYOCARDIAL INFARCTION REPAIR
To detect cardiomyocytes derived from clonal MSCs
(CMG cells [5, 6]) with a higher sensitivity and specificity,
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Fig. 2. Mobilization and differentiation of
mesenchymal stem cells (CMG cells) into
cardiomyocytes in vitro and in vivo. (A)
The experimental protocol is shown. The
CMG-ME cells are CMG cells that have
been permanently transfected with a plasmid-
encoding EGFP driven by the myosin light
chain promoter (pMLC2v-EGFP). (B and
C) Cultured CMG-ME cells were treated
with 5-azacytidine and immunoassayed with
anti-GATA4 (red) antibody on day 7 of
culture. GATA4 was expressed in the CMG-
ME cells. Some of the CMG-ME cells be-
came EGFP+ (green). (D and E) At 3 weeks,
CMG-ME cells that were positive for both
EGFP and actinin were observed, indicat-
ing that the cells had differentiated into car-
diomyocytes. (F and G) The myocardium of
infarcted mice transplanted with CMG-ME
cells was analyzed using immunofluorescent
microscopy. The green, red, and blue signals
indicate EGFP, actinin, and nuclei, respec-
tively. EGFP+ actinin+ CMG-ME cells were
observed in the myocardium, indicating that
the CMG-ME cells had been mobilized into
the ischemic myocardium. Actinin and EGFP
expression, driven by the MLC-2v promoter,
was detected, indicating that the cells had dif-
ferentiated into cardiomyocytes (bars indicate
10 lm).
cells transfected with a pMLC2v-EGFP plasmid encoding
EGFP driven by the myosin light chain promoter (CMG-
ME cells) were prepared by selection with G418 and then
treated with 5-azacytidine [13]. Ten days posttreatment,
6% of the cells were positive for EGFP and negative
for actinin but expressed GATA4 (Fig. 2B and C). Af-
ter 3 weeks, most of the EGFP+ cells became actinin+
and developed a rod-like appearance (Fig. 2D and E);
at 4 weeks, they exhibited spontaneous beating. These
findings demonstrate that the CMG-ME cells that were
committed to cardiomyocytes could be detected by the
expression of EGFP in this system.
Uncommitted CMG-ME cells were then transplanted
directly into the bone marrow of lethally irradiated
C3H/He (C3H) mice, myocardial infarction was induced,
and the mice were treated with G-CSF (Fig. 2A). The
myocardium of the five mice was analyzed using im-
munofluorescence and a total of 1034 EGFP+ actinin+
cells in 100 samples (20 samples per mouse) were ob-
served. The number of EGFP+ actinin+ cells from each
group of 20 samples from each mouse was 253, 92, 135,
327, and 227. This result indicated that CMG-ME cells
mobilized from the bone marrow contributed to the re-
generation of the myocardium after myocardial infarc-
tion (Fig. 2F and G). The presence of the EGFP gene in
the infarcted area was also confirmed by PCR analysis
(data not shown). Although the number of detected cells
was lower than that observed in mice transplanted with
whole BM, CMG-derived cardiomyocytes were clearly
visible in the ischemic myocardium. These results sug-
gested that the myosin light chain promoter restricted
EGFP expression to cardiac tissue.
DISCUSSION
Although bone marrow–derived cells were reported to
differentiate into cardiomyocytes after myocardial infarc-
tion [2–4], the identity of specific cell types involved has
not been determined. There are two possibilities. First,
bone marrow–derived HSCs transdifferentiated into car-
diomyocytes. Second, other cell types, such as MSCs,
regenerated cardiomyocytes. To address this issue, we
performed two independent clonal analyses to test which
cell types contribute to cardiomyocyte regeneration. The
results suggest that MSCs, but not HSCs, in bone marrow
play a major role in the regeneration of myocardial tissue
after myocardial infarction.
Purified HSCs and their progeny rarely contributed
to the regeneration of cardiomyocytes even with G-CSF
treatment after single cell transplantation following my-
ocardial infarction induction. On the other hand, whole
bone marrow transplantation resulted in marked increase
of the donor-derived cardiomyocytes after myocardial
infarction and subsequent treatment with G-CSF. The
results suggest that the repopulation of cardiomyocytes
was achieved by nonhematopoietic cells in bone marrow
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rather than HSCs and their progeny. In addition, we
did not detect any EGFP+ MSCs in the CD34− KSL-SP
group, while a precise analysis indicated that around 90%
of the MSCs, assayed as fibroblastic colony-forming units
(CFU-F), were derived from donor mice in the whole
bone marrow transplantation model when the recipient
mice received more than 7 Gy of total body irradiation
[14]. These results led us to focus on the nonhematopoi-
etic population of MSCs in bone marrow as a candidate
for the donor-derived cardiomyocytes.
While HSCs can be purified prospectively according to
their surface phenotypes, such purification is difficult to
achieve for MSCs. Therefore, we used a cell line of MSCs
to clonally identify the origin of bone marrow–derived
cardiomyocytes after myocardial infarction. CMG cells,
previously established from MSCs in the bone marrow of
C3H mice, can differentiate into spontaneously beating
cells with a fetal ventricular cardiomyocytes phenotype
in vitro after exposure to 5-azacytidine [5, 6]. Since only
a small fraction of these cells differentiate into cardiomy-
ocytes and CMG cells were sporadically found in other
organs after intrabone marrow injection, we labeled the
CMG cells to improve specific detection. Although the
number of detected cells was smaller than that observed
in mice transplanted with whole bone marrow, CMG-
derived cardiomyocytes were clearly detected in the is-
chemic myocardium; these results are the first evidence
that CMG cells can differentiate into cardiomyocytes in
the cardiac niche without 5-azacytidine treatment. Most
of the CMG cells that were transplanted directly into the
bone marrow differentiated into bone tissue. A limita-
tion of these experiments is that the CMG cell popula-
tion isolated in vitro might not be a natural cell lineage.
An important future experiment is to determine whether
authentic MSCs purified from the bone marrow can re-
generate cardiomyocytes using the protocol outlined in
Figure 2A.
Human MSCs were reported to mobilize into the sys-
temic circulation as a result of G-CSF treatment [15].
The present study also shows that G-CSF treatment in-
duces mobilization of MSCs from the bone marrow into
the systemic circulation leading to engraftment at pe-
ripheral organ sites. Matrix metalloproteinases and elas-
tase, released mainly from granulocytes, are thought to
be the major mediators of HSCs mobilization induced by
G-CSF [16]. The role of these factors in mediating the
mobilization of MSCs is unknown and provides an im-
portant avenue for future research. As G-CSF treatment
following myocardial infarction is reported to improve
cardiac function and survival [4], MSC mobilization may
provide a new strategy for regenerative treatment. Fur-
thermore, the data presented here support the concept
that one function of MSCs in bone marrow is to con-
tribute to the repair of injured tissue by being mobilizing
to the site of injury and differentiating according to the
niche [16, 17]. The clinical significance of cardiomyocyte
regeneration by bone marrow–derived cells must take
into account the role of different populations of cells in
the regeneration process. The outcome of this research
should be the development of novel cytokine and cell-
based therapies for myocardial infarction.
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